Emerging Trends in Beta Cell Therapy for Type 1 Diabetes Treatments
KOBRA Reports · 2026
DOI: 10.64066/kobrareports.25.0018 ↗Kurz gefasst
Fachartikel in der Zeitschrift KOBRA Reports, 2026. Verfasst von Jaewoo Lee. Die Arbeit nennt 8 Literaturangaben. Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT, South Korea.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 1 diabetes is an autoimmune disease that destroys insulin-producing beta cells, leading to acute complications and requiring lifelong insulin injections.With growing interest and medical needs, especially in the United States due to rising obesity and diabetes rates, beta cell-based therapy is advancing.In the U.S., research groups and biotechnology companies are developing cutting-edge technologies, such as stem cell-derived beta cells with injectable scaffolds, which can protect beta cells from immune responses.These approaches are already undergoing clinical trials.Meanwhile, research in Korea is mainly focused on polymer encapsulation.Although these studies have demonstrated effective blood glucose regulation in animal models, challenges remain in maintaining long-term viability of the transplanted beta cells and functional stability.Ongoing international collaboration and knowledge exchange will help accelerate the development of long-term, safe, and effective technologies for type 1 diabetes treatment.
Förderung
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea
Zitieren
APA
Lee, J. (2026). Emerging Trends in Beta Cell Therapy for Type 1 Diabetes Treatments. KOBRA Reports. https://doi.org/10.64066/kobrareports.25.0018
Vancouver
Lee J. Emerging Trends in Beta Cell Therapy for Type 1 Diabetes Treatments. KOBRA Reports. 2026. doi:10.64066/kobrareports.25.0018
BibTeX
@article{Lee2026,
author = {Lee, Jaewoo},
title = {Emerging Trends in Beta Cell Therapy for Type 1 Diabetes Treatments},
journal = {KOBRA Reports},
year = {2026},
doi = {10.64066/kobrareports.25.0018}
}
EUVIMED